Efficient Predictor for Immunotherapy Efficacy: Detecting Pan‐Clones Effector Tumor Antigen‐Specific T Cells in Blood by Nanoparticles Loading Whole Tumor Antigens by Weibiao Zeng, Jin Wang, Zhike Chen, Jian Yang, Ao Zhu, Yan Zheng, Xianlan Chen, Yuhan Liu, Leilei Wu, Yufeng Xie, Sheng Ju, Jun Chen, Cheng Ding, Chang Li, Xin Tong, Mi Liu, Jun Zhao

“…ETASTs in patients with lung cancer are higher than those in healthy individuals and those with benign pulmonary nodules. …”
Get full text

In vitro anticancer effects of frankincense and its nanoemulsions for enhanced cancer cell targeting by Rayya A. Al-Balushi, Aiswarya Chaudhuri, Raghuram Kandimalla, Ashanul Haque, Khalaf M. Alenezi, Mohd. Saeed, Mohammad Changez, Thuraya Al Harthy, Mohammed Al Hinaai, Samra Siddiqui, Ashish Kumar Agrawal, Farrukh Aqil, Farrukh Aqil

“…Cytotoxicity, wound healing, mitochondrial membrane potential (MMP), and reactive oxygen species (ROS) assays were performed against breast cancer (MDA-MB-231, MDA-MB-231-TR) and lung cancer (A549, A549-TR, H1299) cell lines.ResultsThe optimized FO-NEs exhibited an average particle size of 65.1 ± 4.21 nm, a PDI of 0.258 ± 0.04, and a zeta potential of −22.3 ± 1.2 mV. …”
Get full text

Deep learning-based synthetic CT for dosimetric monitoring of combined conventional radiotherapy and lattice boost in large lung tumors by Hongwei Zeng, Xiangyu E, Minghe Lv, Su Zeng, Yue Feng, Wenhao Shen, Wenhui Guan, Yang Zhang, Ruping Zhao, Jingping Yu

“…Methods This study employed cone-beam computed tomography from 115 lung cancer patients to develop a U-Net +  + deep learning model for generating synthetic CT (sCT). …”
Get full text

Krebs von den Lungen-6 surveillance in immune checkpoint inhibitor-induced pneumonitis by Isamu Okamoto, Kazuya Tsubouchi, Ryosuke Matsukane, Shoji Nakamura, Haruna Minami, Yasuto Yoneshima, Kojiro Hata, Sai Yasukochi, Kimitaka Suetsugu, Takeshi Hirota

“…We evaluated the feasibility of using Krebs von den Lungen-6 (KL-6), a marker for interstitial pneumonitis, as a screening tool for pneumonitis.Methods We examined 500 patients with cancer divided into two groups: those with cancer other than non-small cell lung cancer (NSCLC) (Group 1, n=382) and those with NSCLC (Group 2, n=118). …”
Get full text

Coupled CRC 2D and ALI 3D Cultures Express Receptors of Emerging Viruses and Are More Suitable for the Study of Viral Infections Compared to Conventional Cell Lines by Siyu Xia, Jun Liu, Yan Yang, Ming Wu, Lina Ye, Si Chen, Tao Zhang, Zhihong Zeng, Kang Zhang, Kaihong Cai, Xiang Long, Wenbin Gao, Shisong Fang, Hui Li

“…These cells were permissive to the infection of pandemic influenza H1N1 (H1N1pdm). In contrast, the lung cancer cell line A549 and immortalized airway epithelial cells (16HBE) were not susceptible to H1N1 infection. …”
Get full text

Outcome of critically ill patients receiving systemic chemotherapy on the intensive care unit by Panagiotis Karagiannis, Felix Klingler, Viktor Arelin, Winfried Alsdorf, Christina König, Kevin Roedl, Walter Fiedler, Katja Weisel, Stefan Kluge, Carsten Bokemeyer, Dominic Wichmann

“…Predominant disease entities included lymphoma (43%) and acute myeloid leukemia (29%) among hematological patients, and lung cancer (47%) and gastrointestinal malignancies (17%) among solid tumor patients. …”
Get full text

High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC by Alexandre Reuben, Mehmet Altan, Latasha Little, Jianjun Zhang, Ajay Sheshadri, Hai T Tran, Mara B Antonoff, Stephen G Swisher, John V Heymach, Saumil Gandhi, Natalie Vokes, Ziyi Li, Ruoxing Li, Runzhe Chen, Joshua Baguley, Jefferson Sinson, Greg Lizee

“…We used T-cell receptor (TCR) sequencing to systematically analyze prospectively collected patient blood samples from a randomized clinical trial of dual immune checkpoint inhibitor therapy to evaluate changes in the T-cell repertoire and their association with response and irAEs.Methods Patients with immunotherapy-naïve metastatic non-small cell lung cancer (NSCLC) were treated with ipilimumab and nivolumab according to trial protocol (LONESTAR, NCT03391869). …”
Get full text

Evaluation of patient immunocompetence for immune checkpoint inhibitor therapy using the psoas muscle index: a retrospective cohort study by Toshiaki Tsurui, Toshiaki Tsurui, Toshiaki Tsurui, Toshiaki Tsurui, Kazuyuki Hamada, Emiko Mura, Risako Suzuki, Nana Iriguchi, Tomoyuki Ishiguro, Yuya Hirasawa, Ryotaro Ohkuma, Masahiro Shimokawa, Hirotsugu Ariizumi, Yutaro Kubota, Atsushi Horiike, Satoshi Wada, Satoshi Wada, Kiyoshi Yoshimura, Kiyoshi Yoshimura, Mayumi Tsuji, Yuji Kiuchi, Yuji Kiuchi, Takuya Tsunoda

“…However, the association between sarcopenia and the response to immune checkpoint inhibitor (ICI) therapy remains unclear.MethodsThis retrospective study included patients with advanced or recurrent non-small cell lung cancer treated with nivolumab or pembrolizumab monotherapy. …”
Get full text

Impact of Bone-Modifying Agents on Post-Bone Metastasis Survival Across Cancer Types by Hironari Tamiya, Kazumi Nishino, Yuji Kato, Reina Nakahashi-Kato, Yurika Kosuga-Tsujimoto, Shota Kinoshita, Rie Suzuki, Makiyo Watanabe, Toru Wakamatsu, Shigeki Kakunaga, Satoshi Takenaka

“…In contrast, median post-bone metastasis survival was significantly shorter in gastrointestinal (GI) (6.5 months), head and neck (6.3 months), and urinary tract (3.4 months) cancers. In non-small cell lung cancer (NSCLC), the log-rank test demonstrated that the epidermal growth factor receptor (EGFR) mutation was a significant factor for post-bone metastasis survival: EGFR mutation (−) <i>n</i> = 67, median post-bone metastasis survival 11.5 months (95% CI: 6.0–15.2); EGFR mutation (+) <i>n</i> = 39, median post-bone metastasis survival 28.8 months (95% CI: 18.1–35.7) (<i>p</i> < 0.05). …”
Get full text

Impact of crack cocaine on salivary nucleic acids, enzymes, esters, and lipids: A fourier-transform infrared spectroscopy study by Gabriela Ribeiro Zucco, Taís Maria Cardoso de Oliveira, Thaís Xavier Pereira da Silva, Sandra Silva Marques, Fernando Sabbag, Marcelo Ribeiro de Araújo, Rodrigo Melim Zerbinati, Paulo Henrique Braz-Silva, José Ângelo Lindoso, Gabrielle Luana Jimenez Teodoro Nepomuceno, Letícia Foiani, Herculano da Silva Martinho, Janete Dias Almeida

“…Salivary biomarkers revealed clinical implications, including findings related to xerostomia, caries, and periodontal or systemic conditions such as lung cancer. Conclusion: The research uncovers significant compositional differences in the saliva of current users, former users, and non-users of crack. …”
Get full text

Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types by Jeffrey S Ross, Richard S P Huang, Jake G Maule, Lani K Clinton, Ryon P Graf, Jinpeng Xiao, Geoffrey R Oxnard

“…A total of 81.1% (43/53) lung squamous cell carcinoma, 72.1% (88/122) of lung adenocarcinoma, 69.6% (16/23) of non-small cell lung cancer (NSCLC) not otherwise specified (NOS), and 50.0% (4/8) of small cell lung carcinoma cases were positive with at least one IHC assay.Conclusions Our data suggest that 22C3 is the most sensitive PD-L1 IHC assay for tumor cell expression, followed by 28-8 and in turn by SP-142. …”
Get full text

Predictive value of ENLIGHT-DP in patients with metastatic lung adenocarcinoma treated with immune checkpoint inhibitors and platinum chemotherapy directly from histopathology slid... by Eli Pikarsky, Anna Elia, Gal Dinstag, Omer Tirosh, Tuvik Beker, Ranit Aharonov, Hovav Nechushtan, Leon Gugel, Yaron Kinar, Michael Tabi, Tzivia Gottlieb, Aron Popovtzer, Johnathan Arnon, Yakir Rottenberg, Philip Blumenfeld

“…Introduction Immune checkpoint inhibitors (ICI) have improved outcomes in non-small cell lung cancer (NSCLC). Nevertheless, the clinical benefit of ICI as monotherapy or in combination with chemotherapy remains widely varied and existing biomarkers have limited predictive value. …”
Get full text

Early Outcomes from Proton Craniospinal Irradiation for Leptomeningeal Metastasis From Solid Tumors by Keng Lam, MD, Lewis F. Nasr, MD, Clark R. Andersen, MS, Kathryn E. Marqueen, MD, Jing Li, MD, PhD, Chenyang Wang, MD, Thomas H. Beckham, MD, PhD, Nazanin K. Majd, MD, PhD, Ashley E. Aaroe, MD, Monica Loghin, MD, Barbara J. O'Brien, MD, Susan L. McGovern, MD, PhD

“…Breast cancer (53%), lung cancer (20%), and melanoma (9%) were the most common primary cancers; 51% of patients had stable systemic disease at LM diagnosis. …”
Get full text

Identification of novel pQTL‐SNPs associated with lung adenocarcinoma risk: A multi‐stage study by Yutong Wu, Huiwen Xu, Liping Mao, Rongrong Zhao, Junfeng Chu, Lili Huang, Wendi Zhang, Yiran Liu, Qiong Chen, Xiaobo Tao, Siqi Li, Shenxuan Zhou, Anhui Ning, Zhenyu Li, Tian Tian, Lei Zhang, Jiahua Cui, Guangyu Tian, Minjie Chu

“…The associations between selected pQTL‐SNPs and LUAD risk were evaluated by Female Lung Cancer Consortium in Asia GWAS (FLCCA GWAS). Enzyme linked immunosorbent assay (ELISA) is used to determine the levels of candidate protein. …”
Get full text

Comparative analysis of cancer statistics in China and the United States in 2024 by Yujie Wu, Siyi He, Mengdi Cao, Yi Teng, Qianru Li, Nuopei Tan, Jiachen Wang, Tingting Zuo, Tianyi Li, Yuanjie Zheng, Changfa Xia, Wanqing Chen, Jing Ni

“…The highest estimated cancer cases are lung cancer in China and breast cancer in the US. The age-standardized incidence rates of lung and colorectal cancer in the US, and stomach, liver, and esophageal cancer in China have decreased, but the incidence rates of liver cancer in the US and colorectal cancer, prostate cancer in men, and cervical cancer in women in China have increased. …”
Get full text

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis by Shang‐Gin Wu, Chao‐Chi Ho, James Chih‐Hsin Yang, Shu‐Han Yu, Yen‐Feng Lin, Shu‐Chin Lin, Bin‐Chi Liao, Ching‐Yao Yang, Yen‐Ting Lin, Chong‐Jen Yu, Ya‐Ting Chuang, Wei‐Yu Liao, Kah Yi Yap, Weng Si Kou, Jin‐Yuan Shih

“…Abstract Background Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) remains a significant hurdle for patients with EGFR‐mutated non‐small cell lung cancer (NSCLC), particularly those lacking the EGFRT790M. …”
Get full text

PKCα regulates the secretion of PDL1-carrying small extracellular vesicles in a p53-dependent manner by Ren Zhang, Weilin Liao, Xi Chen, Junyi Wang, Jiaqi Li, Geer Chen, Weiyu Wu, Xiaoxuan Wang, Yao Zhang, Ziyu Chen, Xiaoyu Zhu, Zicong Lin, Yizhun Zhu, Lijuan Ma, Haijie Yu

“…Intracellular calcium and the associated downstream PKC signaling plays pivotal roles in releasing PD-L1 sEVs in non-small cell lung cancer cells (NSCLC). Particularly, we observed that knocking down PKCα has profound impacts on PD-L1 sEVs secretion, especially in the resting state and in the activated state, when induced by an intracellular calcium rise. …”
Get full text

Lutetium-177 labeled iPD-L1 as a novel immunomodulator for cancer-targeted radiotherapy by Myrna Luna-Gutiérrez, Erika Azorín-Vega, Rigoberto Oros-Pantoja, Blanca Ocampo-García, Pedro Cruz-Nova, Nallely Jiménez-Mancilla, Gerardo Bravo-Villegas, Clara Santos-Cuevas, Laura Meléndez-Alafort, Guillermina Ferro-Flores

“…On the other hand, anti-PD-L1 immunotherapy in combination with external beam radiotherapy has shown improved outcomes in the treatment of breast and lung cancer. The aim of this research was to prepare 177Lu-labeled iPD-L1 and to preclinically evaluate its radiotherapeutic potential and role as a tumor immunomodulator by measuring macrophage activation, IL-10, TGFβ, and PD-L1 expression in 4T1 triple-negative breast cancer cells and murine 4T1 tumors after treatment with 177Lu-iPD-L1. …”
Get full text

Sleep Pattern, Lifestyle Pattern, and Risks of Overall and 20 Types of Cancers: Findings From the UK Biobank Cohort by Yue-Ze Zhao, Yue-Ze Zhao, Wen-Li Zhang, Kai-Wen Zhang, Yong-Qiao He, Wen-Qiong Xue, Da-Wei Yang, Da-Wei Yang, Hua Diao, Hua Diao, Ruo-Wen Xiao, Ying Liao, Qiao-Ling Wang, Qiao-Ling Wang, Wei-Hua Jia, Wei-Hua Jia, Tong-Min Wang

“…Participants with healthy sleep and lifestyle patterns had a lower risk of overall cancer (HR = 0.72, 95% CI = 0.68–0.77), liver cancer (HR = 0.53, 95% CI = 0.31–0.90), bladder cancer (HR = 0.61, 95% CI = 0.47–0.79), lung cancer (HR = 0.22, 95% CI = 0.19–0.27), and colorectal cancer (HR = 0.80, 95% CI = 0.66–0.96) compared to those with unhealthy patterns.ConclusionOur findings highlight the importance of public health education and interventions to improve sleep and other lifestyle behaviours for cancer prevention.…”
Get full text

Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in pat... by Christy Ralph, Sumati Gupta, Matthew Zibelman, Brendan D Curti, Kevin J Harrington, Steven J O'Day, Andrew G Hill, David C Campbell, Gavin M Wright, David E Gerber, Jonathan E Rosenberg, Jaime R Merchan, Charles M Rudin, Hardev S Pandha, Wallace L Akerley, Daphne Day, Timothy D Clay, Ross R Jennens, Yixin Ren, Emmett V Schmidt, Lisa Guttman

“…This phase 1 study evaluated intravenous V937±pembrolizumab in patients with advanced solid tumors.Methods Patients had advanced non-small cell lung cancer (NSCLC), urothelial cancer, metastatic castration-resistant prostate cancer, or melanoma in part A (V937 monotherapy), and metastatic NSCLC or urothelial cancer in part B (V937+pembrolizumab). …”
Get full text